Christina M. Annunziata, MD, PhD

Articles by Christina M. Annunziata, MD, PhD

A Study of Olaparib and Cediranib in Ovarian Cancer

March 22nd 2017

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Latest Updated Articles

A Study of Olaparib and Cediranib in Ovarian Cancer
March 22nd 2017